Research outputs
Despite being small, CBR at York leads an internationally recognised fundamental and applied clinical research portfolio.
Since 2017 we've attracted almost £22m in active research funding (MRC, NIHR, CRUK, Gates Foundation, Blood Cancer UK and industrial partnerships) and publish in leading journals (Science, Nature, Cell Stem Cell, Science Translational Medicine, Cancer Discovery, Blood, Nature Communications and Lancet Haematology).
CBR at York has a number of industrial collaborations some of which have led to Phase I clinical trials (INCA033989 monoclonal antibody - Incyte), we produce evidence that impacts on NICE (National Institute for Health and Care Excellence) treatment guidelines for haematological malignancies (leukaemia, lymphoma and myeloma) and run national clinical trials in haematology (eg UKALL15, FLAIR).
Research Impact
CBR at York has an ambitious vision to catapult Yorkshire and the Humber to the forefront of blood research through:
- policy making and clinical guidance
- high-impact publications
- development of biologics and technologies
- patient and public Involvement (PPI)
- engagement with industry
- clinical training.
Our key objective is to contribute to society and to cultivate future talent through strategic and sustainable expansion.
Recent publications
Take a look at our publications list, which brings together a wide breadth of relevant outputs.